


Healthcare Industry News: HIV/AIDS
News Release - September 29, 2006
Bristol-Myers Squibb and Gilead Sciences establish agreement to commercialize ATRIPLA(TM) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Canada
Source: Bristol-Myers Squibb
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
